WO2025161939 - ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/161939
Publication Date
07.08.2025
International Application No.
PCT/CN2025/072194
International Filing Date
14.01.2025
Title **
[English]
ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
ZHANG, Yifu
YAO, Fengping
SHANG, Chengzhang
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2024/074851
31.01.2024
CN
PCT/CN2024/136125
02.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4841 | |
| EPO | Filing, Examination, Granting | 92907 | |
| Japan | Filing, Examination, Granting | 4714 | |
| South Korea | Filing, Examination, Granting | 7661 | |
| USA | Filing, Examination, Granting | 29190 |
Total:
139,313
Contact Us
Abstract[English]
Provided are anti-FOLR1 (folate receptor alpha) antibodies, antigen-binding fragments thereof, and antibody-drug conjugate (ADC) derived therefrom; and anti-FOLR1/MUC1 (e.g., multispecific or bispecific) antibodies or antigen-binding fragments thereof, and antibody-drug conjugate (ADC) derived therefrom and uses thereof.[French]
L'invention concerne des anticorps anti-FOLR1 (récepteur alpha du folate), des fragments de liaison à l'antigène de ceux-ci, et un conjugué anticorps-médicament (ADC) dérivé de ceux-ci; et des anticorps anti-FOLR1/MUC1 (par exemple, des anticorps multispécifiques ou bispécifiques) ou des fragments de liaison à l'antigène de ceux-ci, et un conjugué anticorps-médicament (ADC) dérivé de ceux-ci et leurs utilisations.